Award
National Cancer Institute 5R01CA268513-04
Spatially precise radio-chemo-immunotherapy using antibody conjugates
Recipient
University of California, San Diego
Award Amount
$533,079.00
Ceiling
$533,079.00
Awarded
January 13, 2026
Identifier
5R01CA268513-04
The award supports research on antibody-drug conjugates designed to improve the precision and effectiveness of radio-chemo-immunotherapy for locally advanced cancers by targeting tumor cells and minimizing normal tissue damage.
Description
This project focuses on developing targeted antibody-drug conjugates (ADCs) that deliver radiosensitizers specifically to tumor cells, enhancing the efficacy of radiotherapy while minimizing damage to normal tissues. The research involves testing novel ADCs in murine models, evaluating their ability to modulate the tumor immune microenvironment, and combining them with immunotherapies for improved tumor control.